반응식
ClC1C=CC(C([C:12]2[C:20]3[C:15](=[C:16]([CH2:22][S:23][CH3:24])[CH:17]=[C:18]([F:21])[CH:19]=3)[NH:14][CH:13]=2)CCO)=CC=1.[Cl:25][C:26]1[CH:31]=[CH:30][C:29]([CH:32]([C:34]2[CH:39]=[CH:38][C:37]([F:40])=[CH:36][CH:35]=2)O)=[C:28]([F:41])[CH:27]=1.FC1C=CC(C(C2C=CC(F)=CC=2)C2C3C(=C(CSC)C=CC=3)NC=2)=C(C)C=1>>[Cl:25][C:26]1[CH:31]=[CH:30][C:29]([CH:32]([C:34]2[CH:39]=[CH:38][C:37]([F:40])=[CH:36][CH:35]=2)[C:12]2[C:20]3[C:15](=[C:16]([CH2:22][S:23][CH3:24])[CH:17]=[C:18]([F:21])[CH:19]=3)[NH:14][CH:13]=2)=[C:28]([F:41])[CH:27]=1참가 물질
4
반응물 3
생성물 1
실험 절차
The title compound was prepared starting from 500 mg (2.56 mmol) of the compound from Example 9 and 652 mg (2.56 mmol) of the compound from Example 85A in analogy to the synthesis of the compound from Example 101. 197 mg (18% of theory) of the target compound were obtained.
후처리
- custom197 mg (18% of theory) of the target compound were obtained
출처 및 근거
- ORD 기록
- ord-5a3ea31910244963945cedb1786e2dda
- 출처 데이터셋
- uspto-grants-2011_11
- 특허 번호
- US08063234B2
연결된 노트
불러오는 중…